Regeneron (REGN:US) Pharmaceuticals Inc. and Sanofi (SAN) may get a head start on their biggest competitor in bringing a new class of cholesterol drugs to the U.S. market.
The U.S. Food and Drug Administration has until July 24 to make a decision on the companies’ application to market their jointly developed drug alirocumab, Regeneron and Sanofi said in a statement.
Also read: Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
Read more